Scripps Research Logo

Office of
Technology Development

Staff & Responsibilities

Staff Bios

Staff Bios

Matthew Trenblay

Matt Tremblay

Matt joined the Office of Technology Development in November 2016 as Vice President, Business Development, responsible for leading the newly formed joint business development function with California Institute for Biomedical Research (Calibr), a TSRI affiliate institute focused on drug discovery. Matt is also Chief Operating Officer and Secretary to the Board of Directors at Calibr, where he is responsible for the day to day operation of the institute, as well as external relationships with academic, foundation and commercial partners, and works closely with the CEO to develop corporate strategy and advance new business development opportunities. Matt facilitated the launch of a number of strategic initiatives at Calibr, including drug discovery collaborations with the Juvenile Diabetes Research Foundation, the Bill & Melinda Gates Foundation, Bristol-Myers Squibb, and Pfizer. He was involved with research at Calibr since its inception in April 2012, leading a team of biologists in the discovery of new therapeutic agents for metabolic, cardiovascular, and autoimmune diseases. Before joining Calibr, Matt led a group at the Genomics Institute of the Novartis Research Foundation (GNF) in drug discovery for type 1 diabetes. Matt earned his Ph.D. in chemistry from Columbia University in 2007 before spending two years as a postdoctoral fellow in Peter Schultz’s lab at The Scripps Research Institute.

Julia Ronlov

Julia Ronlov

Ms. Ronlov serves as TSRI’s Executive Director of Business Development, where she is responsible for business development strategy and all commercialization activities undertaken by the office. Prior to TSRI, Ms. Ronlov ran strategic partnerships for Oregon Health & Science University’s School of Medicine. Ms. Ronlov has experience managing corporate acquisitions and divestitures for Gen-Probe, and has served as a fundraising, investment and partnering advisor to a wide range of biotechnology and academic organizations, including: UCSD Moores Cancer Center, Kaiser Permanente’s Research Program on Genes, Environment and Health, Somaxon Pharmaceuticals, Sofinnova Ventures, and Avalon Capital Group. Ms. Ronlov began her business career at Forward Ventures, where she closed on over $50 million in equity investments, served as a board director of investee companies and played a key role in raising over $400 million for the firm. Prior to her career in business, Ms. Ronlov performed research in cellular and molecular biology at Viagene (acquired by Chiron), a company developing gene therapy for HIV and melanoma. Ms. Ronlov is active in the nonprofit community and formerly served as board chair of Outdoor Outreach, an organization dedicated to enriching the lives of underprivileged youth. Ms. Ronlov holds a BS in Biological Sciences from California State University, Chico and an MBA from University of San Diego.

Peter Policastro

Peter Policastro

Peter Policastro serves as Senior Director of Business Development for TSRI’s Florida campus. Peter is a seasoned entrepreneur and executive with over twenty years of experience in various leadership roles in the chemical and biotechnology industries. Peter came to TSRI from BCM Technologies Inc., a seed stage venture capital firm affiliated with the Baylor College of Medicine, where he was an Entrepreneur in Residence. Previously, Peter was President and CEO of privately held Sapphire Therapeutics (acquired by Helsinn SA); President and CEO of platform discovery company Enchira Biotechnology Corp (NASDAQ); Senior Vice President for R&D of Borden Chemical’s Plastics Manufacturing Division; Senior Vice President for R&D and Chief Technology Officer of Sun Coast Industries (NYSE); and President of the U.S. research division of OctaNova Industries AB (acquired by Akzo Nobel). In 1992, he founded and served as President and CEO of Medgenesis, Inc., where he was responsible for developing and commercializing medical devices that were used in laser surgical procedures performed in outpatient clinics and hospital operating rooms throughout the US. Peter started his career as a staff scientist at General Electric’s Corporate Research Division, where he went on to direct an interdisciplinary team of scientists involved in the discovery of advanced materials. Peter received his Ph.D. in Organic Chemistry from The Massachusetts Institute of Technology, where his work under Glenn Berchtold, and in collaboration with the laboratory of Chris Walsh, was directed toward elucidation of the Chorismate Pathway. He received an A.B., Magna Cum Laude, in Chemistry from Duke University and he is an inventor of 19 issued U.S. Patents.

Donaldson Santos

Donaldson Santos

Donaldson Santos is the Associate Director, Licensing in the Office of Technology Development and a Certified Licensing Professional (CLP). He is responsible for technology licensing and corporate sponsored research agreements. Prior to joining TSRI, Donaldson was a Licensing Associate at the University of Southern California’s Office of Technology Licensing in Los Angeles, where he gained over five years of experience in the evaluation, protection, marketing and licensing of inventions in a wide variety of life science-related fields, including chemistry, oncology, gene therapy, biology, and immunology. Donaldson also assisted in the creation of faculty start-up companies and taught classes to USC faculty and students on the role and value of intellectual property. Previously Donaldson was a technical sales representative for Stratagene (acquired by Agilent Technologies) selling and marketing life science tools and instruments to academic and commercial biotech customers in the greater Los Angeles/Orange County areas. Donaldson has an undergraduate degree in Biochemistry/Chemistry from the University of California, San Diego.

William Marrs

William Marrs

William Marrs is in a new role as Technology Development Officer. He is responsible for facilitating technology licensing and material transfers for the TSRI community. Prior to joining the technology development group, Will was a postdoctoral research associate in the laboratory of Dr. Larry Parsons in TSRI’s Committee on the Neurobiology of Addictive Disorders. Will’s research has focused on understanding the neurobiological effects of cannabis and alcohol use, as well as exploring the interactions between the immune system and the nervous system in neurological disorders. He has a keen interest in creative ways to enhance the drug development process in order to make useful medicines more widely available to the public. Will holds a B.S. in Neuroscience from the University of California, Los Angeles and a Ph.D. in Neurobiology and Behavior from the University of Washington in Seattle, WA.

Mitchell Wold

Mitchell Wold

Mitchell Wold is a Technology Development Officer where he is responsible for material transfers and technology licensing. Prior to his role at OTD, he earned his PhD from the Icahn School of Medicine at Mount Sinai. His doctoral work was on autophagy regulation and neurodegenerative disease. Before graduate school, Mitchell gained experience in a biotech startup aimed at developing digital-droplet PCR technology and performed basic research on animal models of schizophrenia as an undergraduate. Mitchell holds a B.A. in Behavioral Neuroscience from Western Washington University in Bellingham, WA and a Ph.D. in Neuroscience from the Icahn School of Medicine at Mount Sinai in New York, NY.